Illuminate breast cancer in real-time

Today, approximately 20-40% of lumpectomies result in positive margins and the need for a second invasive procedure.1,2

Breast cancer surgery statistics

Pathology < 0.1% of the lumpectomy specimen surface is examined by pathology.*
Re-excision 20-40% of breast cancer patients require a second surgery.1,2
Residual 19% of patients who have negative margins after lumpectomy have residual cancer.3
Mortality 25% of women who have breast cancer recurrence do not survive.4

what if…

WHAT IF the power to illuminate cancerous tissue was in your hands so you could see inside the breast cavity during surgery, and catch and remove additional cancer that may have otherwise been left behind?

Discover a brand-new vision in real-time excision

Sign up to receive notifications around FDA approval, clinical data and availability.

For more information on Lumicell or on the Lumicell Direct Visualization System**, visit

*Based on comparison of the surface area of a lumpectomy specimen, the number of pathology slides examined and the dimensions of the section

**CAUTION: New Drug and Investigational device. Limited by Federal (or United States) law to investigational use.

References: 1. Wilke LG, Czechura T, Wang C, et al. Repeat surgery after breast conservation for the treatment of stage 0 to II breast carcinoma: a report from the National Cancer Data Base, 2004-2010. JAMA Surg 2014;149:1296-305. 2. McCahill LE, Single RM, Aiello Bowles EJ, et al. Variability in reexcision following breast conservation surgery. JAMA 2012; 307: 467-75. 3. Chagpar AB, Killelea BK, Tsangaris TN, Butler M, et al. A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer. N Engl J Med. 2015 Aug 6;373(6):503-10. 4. Darby, S., et al., Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet, 2011. 378(9804): p. 1707-16.